KR102379555B1 - Composition for the prevention and treatment of skin ailment, including Pleurotus cornucopiae and Rehmannia glutinosa complex extract as an active ingredient - Google Patents

Abstract

The present invention relates to a composition for preventing and treating skin diseases, comprising a complex extract of Pleurotus cornucopiae (variety: sangdari) and rehmannia ( Rehmannia glutinosa ; variety: multiganga) as an active ingredient. The extract of yellow oyster mushroom and Rehmannia glutinosa of the present invention effectively reduces the nitric oxide (NO; nitric oxide) production inhibitory effect and the expression of inflammatory cytokines TNF-α, IL-1β, IL-6, PEG2, iNOS and COX-2 By doing so, it can be usefully used as a pharmaceutical composition for preventing and treating skin diseases, a quasi-drug composition for preventing and improving skin diseases, a cosmetic composition for preventing and improving skin diseases, and a health functional food composition for preventing and improving skin diseases.

Description

Composition for the prevention and treatment of skin diseases, including Pleurotus cornucopiae and Rehmannia glutinosa complex extract as an active ingredient}

The present invention relates to a composition for preventing and treating skin diseases, comprising a complex extract of Pleurotus cornucopiae ( variety: sagebrush) and Rehmannia glutinosa ( variety: Dagang) as active ingredients. More specifically, the present invention relates to a pharmaceutical composition for preventing and treating skin diseases, a quasi-drug composition for preventing and improving skin diseases, a cosmetic composition for preventing and improving skin diseases, and skin comprising a complex extract of yellow oyster mushroom and Rehmannia glutinosa as an active ingredient. It relates to a health functional food composition for preventing and improving diseases.

Contact dermatitis is a type of skin inflammation that causes irritation or an allergic reaction when a substance comes into contact with the skin. According to the cause of inflammation, it is divided into irritant contact dermatitis and allergic contact dermatitis. The redness or itching caused by dermatitis is not contagious or life-threatening, but it can be very uncomfortable, usually confined to the area where the irritant has come into direct contact with, and can occur anywhere on a person's body.

Irritant contact dermatitis is a dermatitis that can cause dermatitis in almost everyone if a certain concentration or higher is stimulated, and the incidence is much higher than that of allergic dermatitis. Rough soap, chemicals, cosmetics including deodorant, and substances such as diapers damage the protective film of the skin, and other factors such as skin condition, area, age, and environmental factors (temperature, humidity) are involved.

In allergic contact dermatitis, an individual's sensitive allergen causes an immune response of the skin. Metals, accessories, perfumes, cosmetics, hair dyes, plants, etc. act as allergens mainly. In the case of strong allergens, a reaction occurs only after one exposure, but if not, the reaction occurs through repeated contact.

On the other hand, atopic dermatitis is a chronic allergic inflammatory skin reaction that is common in children and can persist into adults. If a family member has other allergic diseases such as asthma or allergic rhinitis, atopic dermatitis is more likely to occur, and it can be caused by allergens such as food or house dust mites. In addition, any factors that irritate the skin, such as sudden changes in room temperature and humidity, sweat or scratching the skin, can cause or worsen symptoms. About 10% of infants in developed countries suffer from atopic dermatitis, which also appears based on a genetic predisposition. 75% of children with atopic dermatitis show symptoms before 6 months of age and disappear by the age of 5, but most of them progress to allergic rhinitis or asthma. Some suffer from atopic dermatitis for the rest of their lives.

The main cause of atopic dermatitis is heredity. In particular, if the mother has atopic dermatitis, the child is also more likely to suffer from atopic dermatitis. As a result of a recent survey by Samsung Seoul Hospital, when looking at the rate of atopic dermatitis when a baby turns one year old, 41.7% of cases where both parents suffered from allergic diseases, 30% of cases where only the mother had it, and 22.2% of cases where only the father suffered from it. , 14.7% of the parents had no allergies. Atopic dermatitis is a disease caused by an imbalance in the immune regulation function that defends the body from the surrounding environment. For example, pollen, house dust mites, cat or dog animal hair, etc., which do not cause any problems in normal people, enter the respiratory tract or cause problems through skin contact. It may worsen or recur. Symptoms of atopic dermatitis are usually itchy, seeping, and blistering and crusting in infancy. Symptoms can appear anywhere on the body, but mainly focus on the face and head. Teenagers and adults have eczema marks on the elbows, knees, ankles, wrists, face, neck, and upper chest.

Currently, most of the treatment methods are symptom relief methods that temporarily relieve itching and inflammation by prescribing a steroid ointment from a dermatologist, or focusing on skin moisturizing is all that is needed.

On the other hand, yellow oyster ( Pleurotus cornucopiae ) is classified in the genus Oliliaceae, and it occurs in the stumps of old broadleaf trees such as cottonwood and willow from early summer to autumn in Korea, Japan, and northeastern China. The diameter of the cap is 2~6cm, and it is spread widely in a circular shape, the center is turned off in a funnel shape, and the surface is smooth in bright yellow to pale yellow. The wrinkle of the yellow oystertail is white and later turns slightly yellow, and the stem is white or yellow, and the base is joined together. Yellow oyster mushroom, which has a bright yellow color than forsythia, is used for food and is soft and has a lot of fiber, so it is slightly tough, and it is characterized by the smell of flour. In addition, yellow oyster mushroom is effective in treating colds, relieving constipation, and sedating. In particular, it is known that it contains active ingredients such as flurane, which are effective for anti-tumor, lowering cholesterol, and improving immunity.

On the other hand, Rehmannia glutinosa is a herbaceous perennial plant belonging to the family Hyonsengaceae. It is a Chinese plant, has short hairs, and has thick roots and a dark blue color. The root is used as a medicinal herb in oriental medicine. It is called raw jihwang when used as raw, dried jihwang that is used dry, and sukjihwang that is steamed with alcohol. The active ingredient contains catalpol and mannit, and the water-soluble part includes mannitol, stachyose, and glucose. Saengjihwang is a febrile disease. It is used when thirsty, the tongue appears red, and symptoms of constipation and restlessness are present. It is used in combination with other drugs for the purpose of hemostasis in hematemesis, nasal bleeding, and hemorrhoidal bleeding. In addition, it is used for diabetes or acute/chronic rheumatism. Geonjihwang is used when there is bleeding during pregnancy by controlling the woman's menstruation. In addition, Sukjihwang is effective as an anemia treatment agent, and is effective for decline in reproductive function, chronic nephritis, hypertension, diabetes, neurasthenia, etc.

The present invention confirmed that the complex extract of Pleurotus cornucopiae and Rehmannia glutinosa effectively reduces the expression of inflammatory cytokines TNF-α, IL-1β, IL-6, PEG2, iNOS and COX-2. It can be used in a composition for preventing and treating skin diseases, and it is derived from natural products and has no side effects, so a pharmaceutical composition for preventing and treating skin diseases, a quasi-drug composition for preventing and improving skin diseases, a cosmetic composition for preventing and improving skin diseases, and skin diseases The present invention was completed by confirming that it can be utilized in a health functional food composition for prevention and improvement.

delete

Republic of Korea Patent Publication No. 10-2017-0073974 (2017.06.29.)

In order to solve the above problems, the present invention prevents skin diseases comprising, as active ingredients, a complex extract of Pleurotus cornucopiae ( Pleurotus cornucopiae ; Variety: Jangdari) and Rehmannia glutinosa ; and to provide a composition for treatment.

In order to solve the above problems, the present invention provides a pharmaceutical composition for preventing and treating skin diseases comprising a complex extract of yellow oyster ( Pleurotus cornucopiae ; cultivar: Jangdari) and rehmannia glutinosa ( Rehmannia glutinosa ; cultivar: multigrass) as an active ingredient. to provide.

In addition, the present invention provides a pharmaceutical composition for preventing and treating skin diseases comprising a complex extract of Pleurotus cornucopiae (variety: Jangdari) and Rehmannia glutinosa (variety: multiganga) as an active ingredient.

In addition, the present invention provides a quasi-drug composition for preventing and improving skin diseases comprising a complex extract of Pleurotus cornucopiae (variety: Jangdari) and Rehmannia glutinosa (variety: Dagang) as active ingredients.

In addition, the present invention provides a cosmetic composition for preventing and improving skin diseases, comprising a complex extract of Pleurotus cornucopiae (variety: sagebrush) and rehmannia glutinosa (variety: multiganga) as active ingredients.

In addition, the present invention provides a health functional food composition for preventing and improving skin diseases, comprising a complex extract of yellow oyster ( Pleurotus cornucopiae ; variety: Jangdari) and rehmannia ( Rehmannia glutinosa ; variety: multiganga) as an active ingredient.

The complex extract of Pleurotus cornucopiae and Rehmannia glutinosa of the present invention effectively reduces the expression of inflammatory cytokines TNF-α, IL-1β, IL-6, PEG2, iNOS and COX-2, It can be used in a composition for preventing and treating diseases, and it is derived from natural products and has no side effects, so a pharmaceutical composition for preventing and treating skin diseases, a quasi-drug composition for preventing and improving skin diseases, a cosmetic composition for preventing and improving skin diseases, and prevention of skin diseases And it can be used variously as a health functional food composition for improvement.

1 is NO production inhibition according to the mixing ratio of the extract of yellow oyster mushroom and the extract of Rehmannia glutinosa (weight ratio after freeze-drying 8:1, 4:1, 2:1, 1:1, 1:2, 1:4, 1:8) It is a diagram confirming the optimal mixing ratio of 4:1 by examining the effect.
Figure 2 is a diagram confirming that the optimal complex extract (4:1) effectively reduces the expression of inflammatory cytokines TNF-α (a), IL-1β (b), IL-6 (c) and PEG2 (d) am.
3 is a diagram confirming that the optimal complex extract (4:1) effectively reduces the expression of inflammatory cytokines iNOS (a) and COX-2 (b).

An object of the present invention is to provide a pharmaceutical composition for the prevention and treatment of skin diseases comprising a complex extract of yellow oyster mushroom and Rehmannia glutinosa as an active ingredient.

In one embodiment of the present invention, the extract of yellow oyster mushroom and Rehmannia glutinosa according to the present invention may be extracted by hot water extraction, but is not limited thereto.

In one embodiment of the present invention, the extract of yellow oyster mushroom and Rehmannia glutinosa of the present invention may be characterized in that it inhibits the production of nitric oxide.

In one embodiment of the present invention, the extract of yellow oyster mushroom and Rehmannia glutinosa of the present invention may be characterized in that it reduces the expression of inflammatory cytokines, and the inflammatory cytokines are TNF-α, IL-1β, IL-6 , PEG2, iNOS, and COX-2 may be characterized as any one, but is not limited thereto.

In one embodiment of the present invention, the mixing ratio of the yellow oyster mushroom and Rehmannia glutinosa complex extract of the present invention is 8:1, 4:1, 2:1, 1:1, 1:2, 1:4 and 1:8, but is not limited thereto.

In one embodiment of the present invention, the skin disease of the present invention may be characterized as atopic dermatitis or contact dermatitis, and the contact dermatitis may be characterized as irritant dermatitis or allergic dermatitis, but is limited thereto not.

In one embodiment of the present invention, the variety of yellow oysteriasis of the present invention yellow oyster and Rehmannia fertilis complex extract is Jangdari (new variety application No. 2013-208), and the variety of rehmannia is multigange (new variety application No. 2011-587). It may be characterized, but is not limited thereto.

In addition, an object of the present invention is to provide a quasi-drug composition for preventing and improving skin diseases comprising a complex extract of yellow oyster mushroom and rehmannia glutinosa as an active ingredient.

In addition, it is an object of the present invention to provide a cosmetic composition for preventing and improving skin diseases comprising a complex extract of yellow oyster mushroom and Rehmannia glutinosa as an active ingredient.

Finally, it is an object of the present invention to provide a health functional food composition for preventing and improving skin diseases, comprising a complex extract of yellow oyster mushroom and rehmannia glutinosa as an active ingredient.

Hereinafter, the present invention will be described in detail by way of embodiments of the present invention with reference to the accompanying drawings. However, the following embodiments are presented as examples of the present invention, and when it is determined that detailed descriptions of well-known techniques or configurations known to those skilled in the art may unnecessarily obscure the gist of the present invention, the detailed description may be omitted, , the present invention is not limited thereby. Various modifications and applications of the present invention are possible within the scope of equivalents interpreted therefrom and the description of the claims to be described later.

In addition, terms used in this specification are terms used to properly express preferred embodiments of the present invention, which may vary depending on the intention of a user or operator or customs in the field to which the present invention belongs. Therefore, definitions of these terms should be made based on the content throughout this specification. Throughout the specification, when a part "includes" a certain element, it means that other elements may be further included, rather than excluding other elements, unless otherwise stated.

Throughout this specification, '%' used to indicate the concentration of a specific substance is (w/w) % for solid/solid, (w/v) % for solid/liquid, and Liquid/liquid is (v/v) %.

In one aspect, it relates to a pharmaceutical composition for preventing and treating skin diseases, comprising the extract of yellow oyster mushroom and Rehmannia glutinosa as an active ingredient.

The extract according to the present invention may be obtained by extraction and separation from nature using an extraction and separation method known in the art, and the “extract” as defined in the present invention is obtained from A. It is extracted, and includes, for example, a crude extract, a polar solvent-soluble extract, or a non-polar solvent-soluble extract. As a suitable solvent for extracting the extract from Yellow oyster or Rehmannia glutinosa, any pharmaceutically acceptable organic solvent may be used, and water or an organic solvent may be used, but is not limited thereto, for example, purified water , methanol (methanol), ethanol (ethanol), propanol (propanol), isopropanol (isopropanol), butanol (butanol), including alcohols having 1 to 4 carbon atoms, acetone (acetone), ether (ether), benzene (benzene) Various solvents such as , chloroform, ethyl acetate, methylene chloride, hexane and cyclohexane may be used alone or in combination. As the extraction method, any one of methods such as hot water extraction, cold extraction, reflux cooling extraction, solvent extraction, steam distillation, ultrasonic extraction, elution, and compression may be selected and used. In addition, the desired extract may be further subjected to a conventional fractionation process, and may be purified using a conventional purification method.

There is no limitation on the method for preparing the extract of the present invention, and any known method may be used. For example, the extract included in the composition of the present invention may be prepared in a powder state by an additional process such as distillation under reduced pressure and freeze-drying or spray-drying the primary extract extracted by the hot water extraction or solvent extraction method described above. In addition, the first extract was further purified using various chromatography methods such as silica gel column chromatography, thin layer chromatography, high performance liquid chromatography, etc. you may get Therefore, in the present invention, the extract is a concept including all extracts, isolated compounds, fractions and purified substances obtained in each step of extraction, fractionation or purification, and dilutions, concentrates or dried substances thereof.

The pharmaceutical composition of the present invention may further include an adjuvant in addition to the active ingredient. The adjuvant can be used without limitation as long as it is known in the art, for example, Freund's complete adjuvant or incomplete adjuvant can be further included to increase the immunity thereof.

The “pharmaceutical composition” according to the present invention may be prepared in a form in which the active ingredient is incorporated into a pharmaceutically acceptable carrier. Here, the pharmaceutically acceptable carrier includes carriers, excipients and diluents commonly used in the pharmaceutical field. Pharmaceutically acceptable carriers that can be used in the pharmaceutical composition of the present invention include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin , calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

The pharmaceutical composition of the present invention can be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, or sterile injection solutions according to conventional methods, respectively. there is.

In the case of formulation, it can be prepared using a diluent or excipient such as a filler, extender, binder, wetting agent, disintegrant, surfactant, etc. commonly used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations include at least one excipient in the active ingredient, for example, starch, calcium carbonate, sucrose, lactose, gelatin. It can be prepared by mixing and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid formulations for oral administration include suspensions, solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used diluents, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. can Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized formulations and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used. As the base of the suppository, witepsol, tween 61, cacao butter, laurin fat, glycerogelatin, and the like can be used.

The pharmaceutical composition according to the present invention may be administered to an individual by various routes. Any mode of administration can be envisaged, for example, by oral, intravenous, intramuscular, subcutaneous, intraperitoneal injection.

The pharmaceutical composition may be formulated in various oral or parenteral dosage forms.

Formulations for oral administration include, for example, tablets, pills, hard, soft capsules, solutions, suspensions, emulsifiers, syrups, granules, and the like. crose, mannitol, sorbitol, cellulose and/or glycine), lubricants (eg, silica, talc, stearic acid and its magnesium or calcium salts and/or polyethylene glycol). In addition, the tablet may contain a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidine, and optionally starch, agar, alginic acid. or a disintegrant such as its sodium salt or a boiling mixture and/or absorbent, coloring, flavoring and sweetening agent. The formulation may be prepared by conventional mixing, granulating or coating methods.

In addition, a representative formulation for parenteral administration is an injection formulation, and examples of the solvent for the injection formulation include water, Ringer's solution, isotonic saline, or suspension. The sterile, fixed oil of the injectable preparation may be used as a solvent or suspending medium, and any non-irritating fixed oil including mono- and di-glycerides may be used for this purpose.

In addition, the injection preparation may use a fatty acid such as oleic acid.

In one aspect, it relates to a quasi-drug composition for preventing and improving skin diseases, comprising a complex extract of yellow oyster mushroom and Rehmannia glutinosa as an active ingredient.

As used in the present invention, the term “quasi-drugs” refers to items with a milder action than pharmaceuticals among items used for the purpose of diagnosing, treating, improving, alleviating, treating or preventing diseases of humans or animals, for example, the Pharmaceutical Affairs Act. According to the Article, quasi-drugs exclude products used for medicinal purposes, and include products used for the treatment or prevention of diseases in humans and animals, and products with minor or no direct action on the human body.

In the case of using the complex extract of yellow oyster mushroom and rehmannia glutinosa of the present invention as a quasi-drug additive, it may be added as it is or used together with other quasi-drugs or quasi-drug ingredients, and may be appropriately used according to a conventional method. The mixing ratio with other components used together may be appropriately determined depending on the intended use (eg, prevention, improvement or therapeutic treatment).

Examples of the quasi-drug composition include, but are not limited to, scalp and hair care compositions such as shampoos and conditioners, body cleansers, foams, soaps, masks, ointments, creams, lotions, essences, and sprays.

In one aspect, the present invention relates to a cosmetic composition for preventing and improving skin diseases comprising a complex extract of yellow oyster mushroom and rehmannia glutinosa as an active ingredient.

The “cosmetic composition” of the present invention can be prepared by including a cosmetically effective amount of the complex extract of yellow oyster mushroom and Rehmannia glutinosa of the present invention and a cosmetically acceptable carrier.

As used herein, the term “cosmetic effective amount” refers to an amount sufficient to achieve skin regeneration efficacy through proliferation of epidermal keratinocytes of the composition of the present invention.

The appearance of the cosmetic composition contains a cosmetically or dermatologically acceptable medium or base. It is available in all formulations suitable for topical application, for example solutions, gels, solids, kneaded dry products, emulsions obtained by dispersing the oily phase in an aqueous phase, suspensions, microemulsions, microcapsules, microgranules or, ionic (liposomes) and It may be provided in the form of a non-ionic vesicular dispersant, or in the form of a cream, skin, lotion, powder, ointment, spray or concealer stick. These compositions can be prepared according to conventional methods in the art. The composition according to the invention can also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.

The cosmetic composition according to an embodiment of the present invention is not particularly limited in its formulation, for example, softening lotion, astringent lotion, nourishing lotion, nourishing cream, massage cream, essence, eye cream, eye essence, cleansing It can be formulated into cosmetics such as cream, cleansing foam, cleansing water, pack, powder, body lotion, body cream, body oil, and body essence.

When the formulation of the cosmetic composition of the present invention is a paste, cream or gel, animal fiber, vegetable fiber, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc. This can be used.

When the formulation of the cosmetic composition of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In particular, in the case of a spray, additional chlorofluorohydro It may contain a propellant such as carbon, propane/butane or dimethyl ether.

When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene fatty acid esters of glycol, 1,3-butylglycol oil, glycerol fatty esters, polyethylene glycol or sorbitan.

When the formulation of the cosmetic composition of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester; Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth may be used.

When the formulation of the cosmetic composition of the present invention is surfactant-containing cleansing, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate as carrier components , fatty acid amide ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linolin derivative or ethoxylated glycerol fatty acid ester, and the like can be used.

The cosmetic composition of the present invention includes skin, lotion, cream, essence, pack, foundation, color cosmetics, sun cream, two-way cake, face powder, compact, makeup base, skin cover, eye shadow, lipstick, lip gloss, lip fix, eyebrow pencil It can be applied to cosmetics such as , lotion, and detergents such as shampoo and soap.

The cosmetic composition according to an embodiment of the present invention may further include functional additives and components included in general cosmetic compositions in addition to the complex extract of yellow oyster mushroom and Rehmannia glutinosa. The functional additive may include a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids, and seaweed extract.

In the cosmetic composition of the present invention, a component contained in a general cosmetic composition may be further blended with the functional additive as needed. Other ingredients included include oils and fats, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, UV absorbers, preservatives, bactericides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, fragrances, blood circulation An accelerator, a cooling agent, a limiting agent, purified water, etc. are mentioned.

In one aspect, it relates to a health functional food composition for preventing and improving skin diseases comprising a complex extract of yellow oyster mushroom and rehmannia glutinosa as an active ingredient.

"Health functional food composition" of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients, as in a conventional food composition, in addition to containing the active ingredients, yellow oyster mushroom and rehmannia glutinosa complex extract.

Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. The above-mentioned flavoring agents can advantageously use natural flavoring agents (Taumatin), stevia extract (eg rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.). The food composition of the present invention may be formulated in the same manner as the pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes and health supplements. There is this.

In addition, the food composition includes, in addition to the active ingredient extract, various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and thickeners (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the food composition of the present invention may contain natural fruit juice and pulp for the production of fruit juice beverages and vegetable beverages.

The health functional food composition of the present invention may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, and the like. In the present invention, the functional health food composition refers to food manufactured and processed using raw materials or ingredients useful for the human body according to Act No. 6727 of the Health Functional Food Act, and contains nutrients for the structure and function of the human body. It refers to ingestion for the purpose of obtaining useful effects for health purposes such as regulation or physiological action. The health functional food of the present invention may contain normal food additives, and unless otherwise specified, whether it is suitable as a food additive is related to the item according to the general rules and general test method of food additives approved by the Food and Drug Administration. It is judged according to the standards and standards. The items listed in the 'Food Additives Code' include, for example, chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon pigment, licorice extract, crystalline cellulose, high pigment, and guar gum; Mixed preparations, such as a sodium L-glutamate preparation, a noodle-added alkali agent, a preservative preparation, and a tar color preparation, etc. are mentioned. For example, a health functional food in tablet form is granulated by a conventional method by mixing the active ingredient of the present invention with an excipient, a binder, a disintegrant and other additives, followed by compression molding with a lubricant, etc., or The mixture can be compression molded directly. In addition, the health functional food in the form of tablets may contain a corrosive agent or the like, if necessary. Among health functional foods in the form of capsules, hard capsules can be prepared by filling a mixture of the active ingredient of the present invention with additives such as excipients in ordinary hard capsules. It can be prepared by filling the mixture mixed with the capsule base such as gelatin. The soft capsules may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, if necessary. The health functional food in the form of a ring can be prepared by molding a mixture of the active ingredient of the present invention with an excipient, a binder, a disintegrant, etc. by a known method, and if necessary, it can be coated with sucrose or other skinning agent, Alternatively, the surface may be coated with a material such as starch or talc. The health functional food in the form of granules can be prepared in a granular form by a conventionally known method by mixing a mixture of an excipient, a binder, a disintegrant, etc. of the active ingredient of the present invention, and may contain a flavoring agent, a flavoring agent, etc. can

Hereinafter, the present invention will be described in more detail through examples. However, the above embodiments and experimental examples are presented as examples of the present invention, and when it is determined that detailed descriptions of well-known techniques or configurations known to those skilled in the art may unnecessarily obscure the gist of the present invention, the detailed description will be omitted. , and the present invention is not limited thereto. Various modifications and applications of the present invention are possible within the scope of equivalents interpreted therefrom and the description of the claims to be described later.

Example 1. Preparation of extracts of yellow oyster mushroom and Rehmannia glutinosa

1-1. Preparation of yellow oyster extract

After freeze-drying yellow oyster mushroom (variety: long-dari), it was pulverized. Then, ultrasonic extraction was performed for 1 hour using water. After ultrasonic extraction and concentration, lyophilization was performed to powder each.

1-2. Preparation of Rehmannia Extract

Rehmannia (variety: Dagang) was freeze-dried and then pulverized. Then, ultrasonic extraction was performed for 1 hour using water. After ultrasonic extraction and concentration, freeze-drying was performed to powder each.

1-3. Preparation of yellow oyster mushroom and rehmannia glutinosa complex extract

The powdered yellow oyster mushroom (variety: long-dari) powdered in Example 1-1 and the powdered Rehmannia (variety: Dagang) extract powdered in Example 1-2 were mixed in a weight-based mixing ratio (8:1, 4:1). , 2:1, 1:1, 1:2, 1:4, 1:8).

Example 2. Measurement of nitric oxide (NO) inhibitory activity of yellow oyster and rehmannia complex extract

In order to measure nitric oxide (NO) of yellow oyster mushroom and Rehmannia glutinosa complex extract, the experiment was carried out as follows.

(1) Raw 264.7 cells were cultured in a 6 well plate at 1×10 ⁵ cells/mL for 24 h. The next day, when the cell density reached 80%, it was washed twice with phosphate buffered saline (PBS; Sigma-Aldrich) and cultured for 24 h using a serum-free medium. It was put into the well and stimulated. After 2 h, samples were treated with each concentration (25, 50 and 75 μg/mL), and after 24 h, 100 μl of the supernatant and 100 μl of griess reagent were reacted 1:1 for 10 min, and then at 540 nm with an ELISA reader. The amount of NO production was confirmed by measuring the absorbance.

(2) The control group (no treatment) was cultured under the same conditions by adding the same amount of distilled water as the sample. After incubation, 20 µL of MTT (Sigma-Aldrich) solution prepared at a concentration of 5 mg/mL was added to each well, incubated for 4 h, the culture medium was removed, and dimethyl sulfoxide (DMSO) and ethanol were mixed 1:1. 150 μL of the mixed solution was added to each well, reacted at room temperature for 30 min, and absorbance was measured at 550 nm with an ELISA reader.

(3) In addition, cell viability was measured as the decrease in absorbance of the group with and without the sample solution.

As a result, as shown in FIG. 1 , it was confirmed that the optimal mixing ratio of the yellow oyster mushroom and Rehmannia glutinosa complex extract was 4:1 to most effectively inhibit the generation of nitric oxide (NO).

Example 3. Confirmation of the effect of reducing inflammation-related cytokines of yellow oyster mushroom and rehmannia glutinosa complex extract

In order to confirm the effect of the extract of yellow oyster mushroom and Rehmannia glutinosa on representative inflammatory cytokines TNF-α, IL-1β, IL-6 and PEG2, the experiment was carried out as follows.

(1) Raw 264.7 cells were inoculated and cultured at a concentration of 1×10 ⁵ cells/mL in a 6 well plate, exchanged with a serum-free medium when the cell density reached 80%, and cultured for 24 h with LPS (1 μg/mL) was put into all wells except for the Normal group and stimulated.

(2) After 2 h, samples were treated by concentration and cultured for 24 h. Thereafter, the supernatant was removed, washed twice with PBS, and then the cells were harvested with a scraper.

(3) B16F10 mouse melanoma cells were aliquoted to 5×10 ⁴ cells/well in a 6 well plate, stabilized for 24 hours, and after removing the medium, the sample was treated for 48 hours and washed with PBS to harvest the cells.

(4) Lysis buffer was added to each harvested cell at 30 μL per well to lyse the cells and centrifuged (12,000 rpm, 4°C, 30 min) to remove cell membrane components.

(5) Protein obtained by centrifugation was quantified by Bradford assay, and 20 μL of protein was electrophoresed using 10% SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis). After transferring to PVDF membrane, it was transferred at 60 V for 2 hours or more.

(6) After transfer, the background was removed by leaving it in 5% skim milk for 1 hour. After washing 3 times with 1×TBST, attach the primary antibody (1:1000) for 24 h, wash 5 times with 1×TBST, react with the secondary antibody (1:1000) for 2 h, and then react with the ECL kit (Amersham Pharmacia, England) ) was transferred to the film and measured.

(7) Band density was confirmed by Image Quant LAS-4000 (GE life sciences, Taiwan).

As a result, as shown in FIG. 2, TNF-α (a), IL-1β (b), IL-6 (c) and It was confirmed that the expression of PEG2 (d) was decreased in a concentration-dependent manner.

Example 4. Confirmation of anti-inflammatory effect through gene expression analysis of yellow oyster mushroom and rehmannia complex extract

In order to investigate the anti-inflammatory effects of the extracts of yellow oyster mushroom and Rehmannia glutinosa, the effect on gene expression of iNOS and COX-2 was observed.

(1) Raw 264.7 cells were inoculated and cultured at a concentration of 1×10 ⁵ cells/mL in a 6 well plate, exchanged with a serum-free medium when the cell density reached 80%, and cultured for 24 h, LPS (lipopolysaccharide) 1 μg/ mL was put into all wells except for the Normal group and stimulated, and after 2 h, each concentration was treated and cultured for 24 h.

(2) Thereafter, the culture medium was removed to isolate total RNA, and the cells were washed 3 times with PBS, and then separated using trizol reagent (Invitrogen, Carlsbad, CA, USA).

(3) 2 μg of total RNA of each cell and PCR primer oligonucleotide were mixed with an RT-PCR mixer and RT-PCR was performed. Under the condition of RT, cDNA was prepared by standing at 42 °C for 1 hour, and left at 94 °C for 5 minutes to inactivate reverse transcriptase.

(4) Subsequent PCR conditions are based on repeating the reaction 30 times at 94 for 30 seconds (denaturation step), at 50 °C for 30 seconds (annealing step), and at 72 °C for 90 seconds (extension step). It was adjusted to the optimum condition according to the type. In addition, the amplified cDNA was separated by electrophoresis using 1.2% agarose gel and confirmed with a LAS 4000 image analyzer.

As a result, as shown in FIG. 3 , the expression of iNOS (a) and COX-2 (b), which are factors involved in anti-inflammation, was expressed in a concentration-dependent manner by the extract of yellow oyster mushroom and Rehmannia glutinosa (optimal mixing ratio 4:1). It was confirmed that this was reduced.

Therefore, through the present invention, it was confirmed that the yellow oyster mushroom and Rehmannia glutinosa complex extract is excellent in preventing, improving and treating skin diseases, and it can be used in pharmaceutical compositions, quasi-drugs compositions, cosmetic compositions, and health functional food compositions.

So far, the present invention has been looked at with respect to preferred embodiments thereof.

Those of ordinary skill in the art to which the present invention pertains will understand that the present invention can be implemented in a modified form without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is indicated by the claims rather than the foregoing description, and all differences within the scope equivalent thereto should be construed as being included in the present invention.

Claims (11)

In a pharmaceutical composition for the prevention or treatment of inflammatory skin disease, comprising the complex extract of yellow oyster mushroom and rehmannia glutinosa as an active ingredient,
The mixing ratio according to the weight of the complex extract is any one of 8:1, 4:1, 2:1, 1:1, 1:2, 1:4 and 1:8,
The variety of yellow oysteria is long-dari, and the variety of rehmannia is Dagang,
A pharmaceutical composition for preventing or treating atopic dermatitis or contact dermatitis, an inflammatory skin disease. The method of claim 1,
The composition is characterized in that inhibiting the production of nitric oxide (Nitric oxide), a pharmaceutical composition. The method of claim 1,
The composition is characterized in that it reduces the expression of inflammatory cytokines, a pharmaceutical composition. 4. The method of claim 3,
The inflammatory cytokine is TNF-α, IL-1β, IL-6, PEG2, characterized in that any one of iNOS and COX-2, the pharmaceutical composition. delete delete The method of claim 1,
The contact dermatitis is characterized in that irritant dermatitis or allergic dermatitis, the pharmaceutical composition. delete In a quasi-drug composition for preventing or improving inflammatory skin disease comprising a complex extract of yellow oyster mushroom and Rehmannia glutinosa as an active ingredient,
It is characterized in that 10 parts by weight of the extract is included based on 40 parts by weight of the yellow oyster extract,
The variety of yellow oysteria is long-dari, and the variety of rehmannia is Dagang,
A quasi-drug composition for preventing or improving atopic dermatitis or contact dermatitis, an inflammatory skin disease. In a cosmetic composition for preventing or improving inflammatory skin disease comprising a complex extract of yellow oyster mushroom and Rehmannia glutinosa as an active ingredient,
It is characterized in that 10 parts by weight of the extract is included based on 40 parts by weight of the yellow oyster extract,
The variety of yellow oysteria is long-dari, and the variety of rehmannia is Dagang,
A cosmetic composition for preventing or improving atopic dermatitis or contact dermatitis, an inflammatory skin disease. In a health functional food composition for preventing or improving inflammatory skin disease, comprising the extract of yellow oyster mushroom and Rehmannia glutinosa as an active ingredient,
It is characterized in that 10 parts by weight of the extract is included based on 40 parts by weight of the yellow oyster extract,
The variety of yellow oysteria is long-dari, and the variety of rehmannia is Dagang,
A health functional food composition for preventing or improving atopic dermatitis or contact dermatitis, an inflammatory skin disease.

Images